tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program

Story Highlights
  • Kazia Therapeutics announced a collaboration with QIMR Berghofer for a PD-L1 degrader program.
  • The agreement aims to target cancer therapy resistance, enhancing Kazia’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Kazia Therapeutics ( (KZIA) ) has shared an update.

On October 7, 2025, Kazia Therapeutics announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program, featuring the lead compound NDL2. This innovative cancer immunotherapy targets advanced breast cancer and non-small cell lung cancer, aiming to overcome resistance to current PD-1/PD-L1 therapies. The agreement positions Kazia at the forefront of next-generation immuno-oncology, with plans to integrate NDL2 with its existing assets, potentially enhancing its market position and offering new therapeutic options for stakeholders.

The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Spark’s Take on KZIA Stock

According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.

To see Spark’s full report on KZIA stock, click here.

More about Kazia Therapeutics

Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company is known for its lead program, paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat various forms of cancer. Kazia has been involved in multiple clinical trials for paxalisib and is also developing EVT801, a small molecule inhibitor of VEGFR3, showcasing its commitment to advancing cancer treatment.

Average Trading Volume: 307,151

Technical Sentiment Signal: Strong Sell

Current Market Cap: $9.22M

For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1